Who owns Editas Medicine, Inc. (EDIT)? Elite investor 13F holders
2 tracked elite investors reported holding Editas Medicine, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Editas Medicine Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 7999298.00 USD | 2468919.000000 | Shares | reduce | Original filing |
| D.E. Shaw | Editas Medicine Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 6159246.00 USD | 1901002.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.